HeartSciences (HSCS) Cash from Financing Activities (2022 - 2026)
HeartSciences (HSCS) posted quarterly Cash from Financing Activities of -$63673.0 for Q2 2026, down 163.66% year-on-year from $100028.0 in Q2 2025, and down 104.22% on a QoQ basis from $1.5 million in Q4 2025.
HeartSciences (HSCS) Cash from Financing Activities (2022 - 2026) Analysis & Trends
HeartSciences (HSCS) has reported Cash from Financing Activities for 5 consecutive years, with -$63673.0 the latest figure, recorded in Q2 2026.
- Quarterly Cash from Financing Activities fell 163.66% year-over-year to -$63673.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $5.2 million (up 89.99% YoY) and the FY2026 annual result came in at $8.0 million, up 193.74% from the prior year.
- Cash from Financing Activities eased to -$63673.0 in Q2 2026 per HSCS's latest filing, from $1.5 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for HSCS reached as high as $9.1 million in Q1 2024 and fell as low as -$121522.0 in Q1 2023.
- A 5-year average of $1.6 million and a median of $551683.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 7610.17% — and 2026, when it sank 163.66%.
- Year by year, Cash from Financing Activities stood at -$116392.0 in 2022, then surged by 542.15% to $514629.0 in 2023, then surged by 269.53% to $1.9 million in 2024, then slipped by 20.66% to $1.5 million in 2025, then plunged by 104.22% to -$63673.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$63673.0, $1.5 million, and $3.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | HeartSciences | 2.29 Mn | -1.11 Mn | - | -63,673.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -63,673.00 |
| Apr 30, 2026 | -63,673.00 |
| Oct 31, 2025 | 1.51 Mn |
| Oct 31, 2025 | 1.51 Mn |
| Jul 31, 2025 | 3.65 Mn |
| Jul 31, 2025 | 3.65 Mn |
| Apr 30, 2025 | 100,028.00 |
| Apr 30, 2025 | 100,028.00 |
| Jan 31, 2025 | 180,187.00 |
| Jan 31, 2025 | 180,187.00 |
| Oct 31, 2024 | 1.90 Mn |
| Oct 31, 2024 | 1.90 Mn |
| Jul 31, 2024 | 551,683.00 |
| Jul 31, 2024 | 551,683.00 |
| Apr 30, 2024 | 377,142.00 |
| Apr 30, 2024 | 377,142.00 |
| Jan 31, 2024 | 9.13 Mn |
| Jan 31, 2024 | 9.13 Mn |
| Oct 31, 2023 | 514,629.00 |
| Oct 31, 2023 | 514,629.00 |